A61K 38/47
Acting on glycosyl compounds
Official title: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K38/47 (Acting on glycosyl compounds) appears on 1,383 US grants and 2,595 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,383
- Published applications
- 2,595
- Assignees
- 949
- Inventors
- 3,538
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 4 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 4 | 0 |
| 1993 | 4 | 0 |
| 1994 | 7 | 0 |
| 1995 | 9 | 0 |
| 1996 | 7 | 0 |
| 1997 | 12 | 0 |
| 1998 | 8 | 0 |
| 1999 | 20 | 0 |
| 2000 | 18 | 0 |
| 2001 | 17 | 11 |
| 2002 | 22 | 49 |
| 2003 | 16 | 38 |
| 2004 | 11 | 40 |
| 2005 | 13 | 55 |
| 2006 | 17 | 50 |
| 2007 | 8 | 52 |
| 2008 | 10 | 53 |
| 2009 | 13 | 70 |
| 2010 | 35 | 86 |
| 2011 | 29 | 85 |
| 2012 | 43 | 85 |
| 2013 | 54 | 103 |
| 2014 | 68 | 144 |
| 2015 | 72 | 146 |
| 2016 | 79 | 125 |
| 2017 | 82 | 137 |
| 2018 | 80 | 121 |
| 2019 | 90 | 150 |
| 2020 | 83 | 147 |
| 2021 | 86 | 140 |
| 2022 | 72 | 173 |
| 2023 | 69 | 150 |
| 2024 | 77 | 137 |
| 2025 | 67 | 139 |
| 2026 | 51 | 109 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma22 Sep 2026US 12,742,018 B2Janssen Biotech, Inc.
- Methods for treating symptoms and disorders associated with lysosomal storage diseases15 Sep 2026US 12,734,160 B2Genzyme Corporation
- Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma15 Sep 2026US 12,735,501 B2Janssen Biotech, Inc.
- Recombinant adeno-associated virus compositions and methods for producing same8 Sep 2026US 12,729,385 B2Prevail Therapeutics, Inc.
- Methods for improving physical exercise performance18 Aug 2026US 12,708,613 B2Nomio Nutrition AB
- Cosmetic composition comprising an endolysin and an organic filler8 Oct 2026US 2026/0306385 A1L'oreal
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Intravaginal formulations of gardnerella endolysins8 Oct 2026US 2026/0306591 A1BioNTech SE
- Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof1 Oct 2026US 2026/0295021 A1Halozyme Hypercon, Inc.
- Ph20 polypeptide variants, formulations and uses thereof1 Oct 2026US 2026/0297551 A1Halozyme, Inc.
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- CRISPR-Cas systems and methods for altering expression of gene products483US 8,945,839 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas systems and methods for altering expression of gene products470US 8,771,945 B1Massachusetts Institute of Technology · 2014
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers217US 5,626,863 ABoard of Regents, The University of Texas System · 1997